NESS ZIONA, Israel, July 28, 2010 /PRNewswire/ -- Frost Sullivan is pleased to announce the award of its prestigious 2010 European Influenza Vaccines Technology Innovation Award (http://www.biondvax.com/image/users/128084/ftp/my_files/Documents/BiondV...)to BiondVax Pharmaceuticals (BiondVax) (http://www.biondvax.com/) for their breakthrough work on a universal influenza vaccine. This vaccine, the Multimeric-001, is designed to provide multi-season and multi-strain protection against most influenza virus strains, including both seasonal and pandemic strains, and has the potential to eliminate the need for annual flu vaccination. BiondVax is entering Phase II clinical trials for the development of the Multimeric-001 universal influenza vaccine.
In recent years, with the appearance of new, global pandemics, influenza has emerged as a serious disease, affecting the lives of millions of people. The influenza virus has frequent mutations in its surface proteins, resulting in new viral strains that are unfamiliar to the immune system. As a result, the immune response against the virus is largely ineffective, requiring immunisation using annual influenza vaccines. However, because the currently available influenza vaccines are strain-specific, the vaccines must be reformulated every year, requiring annual immunisations.
BiondVax, based in Israel, is developing a vaccine designed to overcome these limitations. The company's vaccine is composed of several conserved epitopes from the influenza virus which are common to most flu strains and can therefore activate the immune system against any new or existing influenza viral strains.
The Frost Sullivan Technology Innovation Award is being awarded to BiondVax in recognition of the innovative Multimeric-001 vaccine, which is unique in the following respects. First, it activates both antibody-mediated (humoral) and cell-mediated immune responses, significantly enhancing the immunity offered by the vaccine. Second, since the vaccine is composed of multiple conserved epitopes from both Influenza Type A and Type B strains, it would offer cross-strain protection against all seasonal and pandemic influenza viruses and would be resistant to mutations of the influenza virus. Finally, BiondVax's vaccine is manufactured by fermentation in E. coli, a robust and efficient process which is estimated to yield commercial-scale production batches in 6-8 weeks, compared with current egg- and cell-based technologies which take 4-6 months.
Unlike current influenza vaccines, BiondVax's vaccine would not need to be administered every year, and would require booster doses only once in 3-5 years, thus conferring long-term protection.
Pre-clinical studies have confirmed the efficacy of BiondVax's vaccine. In addition, BiondVax has recently concluded two Phase I/II clinical trials, in which the vaccine demonstrated both safety and immunogenicity in both younger and older adults. The company is currently preparing to commence its first Phase II clinical trial, expected to be completed by mid-2011.
BiondVax is honoured to receive this prestigious award from Frost Sullivan, commented Dr. Ron Babecoff, CEO of BiondVax. We believe that our universal influenza vaccine is truly innovative, and has the potential to dramatically change the way in which we protect ourselves against the flu, not only from season to season, but also from any potentially virulent and dangerous pandemic flu strains.
Each year, Frost Sullivan presents this award to a company that has developed an innovative element in a product by leveraging cutting-edge technologies. The award recognizes the value added features and benefits of the product and the increased return on investment it offers customers, which in turn increases customer acquisition and overall market penetration potential.
About Frost Sullivan
Frost Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.awards.frost.com
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDX) (http://www.tase.co.il/TASEEng/General/Company/companyMainData.htm?ShareI...) based in Ness Ziona, Israel, is developing a proprietary, innovative Universal Influenza (flu) Vaccine, the Multimeric-001, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal influenza strains and pandemic influenza strains, such as Swine flu and Avian flu.
BiondVax's technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.
BiondVax has recently successfully concluded two Phase I/II clinical trials for the Multimeric-001 vaccine. The vaccine was shown to be safe and immunogenic in both trials.
(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)
For further information on BiondVax, please visit http://www.biondvax.com
For further information, please contact: Nancy Shapira-Aronovic Public Relations Consultant Gelbart Kahana Shapira Marketing Tel: +972-3-607-0588 Mob: +972-54-486-3888 email@example.com
SOURCE: Biondvax Pharmaceuticals Ltd
CONTACT: For further information, please contact: Nancy Shapira-Aronovic,Public Relations Consultant, Gelbart Kahana Shapira Marketing, Tel:+972-3-607-0588, Mob: +972-54-486-3888, firstname.lastname@example.org